Navigation Links
CytomX Expands Scientific and Clinical Advisory Boards with Leading Experts in Cancer Immunotherapy and Antibody Drug Conjugates
Date:3/2/2015

SOUTH SAN FRANCISCO, Calif., March 2, 2015 /PRNewswire/ -- CytomX, a biotechnology company developing Probody™ therapeutics for the treatment of cancer, today announced the creation of scientific and clinical advisory boards comprised of leading researchers and clinicians in the fields of cancer immunotherapy and antibody drug conjugates.

The new advisory boards will provide guidance to CytomX on the development of its wholly owned pipeline of precision immunotherapies and Probody drug conjugates. The company identified advisors who have led significant advances in their respective fields, both in the research and clinical settings. These advisory boards will augment the company's existing platform scientific advisory board, which will remain focused on continued development of the Probody technology platform.

"Our Probody technology enables a wide array of therapeutic antibody modalities, including immunotherapies, Probody drug conjugates, bispecifics and engineered T-cell therapies. We are excited to be working with such accomplished advisors as we move our proprietary pipeline towards the clinic," said Sean McCarthy, D. Phil., chief executive officer of CytomX. "Our advisory boards will be instrumental in helping us design translational clinical strategies to achieve proof of concept for our highly differentiated programs." 

Immunotherapy Advisory Board

Antibody Drug Conjugate Advisory Board

About CytomX Therapeutics

CytomX Therapeutics develops Probody™ therapeutics for the treatment of cancer. Probodies are masked antibodies that remain inert in healthy tissue but are activated specifically in the disease microenvironment. The Probody approach is designed to blunt systemic toxicities associated with antibodies and expand the therapeutic window of these drugs, unlocking new therapeutic targets. The Company is initially focusing this highly innovative platform to discover and develop new immunotherapy and antibody drug conjugate therapies to treat areas of major unmet medical need in oncology. CytomX has attracted multiple strategic collaborations with industry-leading pharmaceutical companies including Pfizer Inc., ImmunoGen and Bristol-Myers Squibb. CytomX is led by a seasoned and proven management team and is financed by leading life science investors, including Third Rock Ventures, Canaan Partners, Roche Venture Fund and Pfizer Venture Investments. For more information, please visit www.cytomx.com.

Media Contacts:
Canale Communications
Ian Stone
ian@canalecomm.com
619-849-5388

 


'/>"/>
SOURCE CytomX Therapeutics
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Lehigh Valley Expands Fleet of Superbug-Slaying Robots
2. Avillion Expands Leadership Team with Appointment of Ramani Varanasi as Chief Business Officer
3. Fortune 500 Pharmaceutical Company Expands Use of inContact Cloud Contact Center Software Across Multiple Divisions
4. BioDrain Breaks into National Network of Ambulatory Surgical Centers and Expands Installations of its STREAMWAY System throughout the U.S.
5. QIAGEN Expands Pipeline of Promising New Biomarkers for Development of Personalized Healthcare Companion Diagnostics
6. Edison Expands North American Healthcare Sector Coverage With Initiation of Coverage on Bellus Health
7. NextDocs Expands Customer Roster by More Than 10 Percent
8. Sotera Wireless Expands Board Of Directors
9. Novira Therapeutics Expands Management Team with Appointment of Klaus Klumpp, Ph.D., the Former Global Head of Roches Virology Discovery Initiatives, as Vice President Discovery Research
10. Senior Home Care Expands Home Health Telemonitoring into Spring Hill, Fla.
11. QIAGEN Significantly Expands its Offering of Assay Panels for Next-generation Sequencing (NGS) Complemented by Ingenuity Analysis and Interpretation Capabilities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2020)... ... ... right round the corner and the risk of getting caught by influenza is getting higher. ... harbor its effects on us. Already with the sudden outbreak of COVID 19, the mortality ... it has become even more relevant to keep oneself immune from any of disease. CDC ...
(Date:8/27/2020)... ... August 27, 2020 , ... Bridge To A Cure Foundation ... is an adult and pediatric neuro-oncologist who serves on the Board of Directors at ... at Duke University Medical School. , Internationally recognized, Dr. Friedman is a widely published ...
(Date:8/26/2020)... ... August 26, 2020 , ... AseptiScope, a privately funded San Diego, ... the Year by MedTech Outlook. , “AseptiScope is pleased to receive this ... clinicians who wear gloves on their hands, goggles on their eyes, covers on their ...
Breaking Medicine Technology:
(Date:8/31/2020)... CHICAGO (PRWEB) , ... August 31, 2020 , ... In ... Chicago West Loop is donating 10 percent of each hotel room booked with ... House Charities® of Chicagoland & Northwest Indiana (RMHC-CNI) , effective immediately. Donations will ...
(Date:8/31/2020)... ... August 31, 2020 , ... ... outcomes for patients with advanced heart failure, today announced that the company has ... amount of $555,358 from the National Heart, Lung, and Blood Institute of the ...
(Date:8/28/2020)... ... August 28, 2020 , ... ... Craig Mandeville was named an Entrepreneur Of The Year® 2020 Florida Award finalist. ... business leaders whose ambitions deliver innovation, growth and prosperity as they build and ...
(Date:8/28/2020)... ... August 28, 2020 , ... The ... a customized Lighthouse Health & Wellness mobile app and web-portal. NCPCV received a ... Solutions Foundation awards grants each year to organizations, such as Destination Imagination, which ...
(Date:8/28/2020)... ... , ... Integrated Viral Protection (IVP Air) today announced that the ... breakthrough Mobile Biodefense Indoor Air Protection System that is the first system designed and ... reopen equipped with the filtration system on September 8th. , The IVP Air ...
Breaking Medicine News(10 mins):